4.7 Article

Dysregulation of TNFα-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1

Journal

LEUKEMIA
Volume 26, Issue 6, Pages 1293-1300

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2011.357

Keywords

chronic lymphocytic leukemia; necroptosis; LEF1; CYLD

Funding

  1. National Natural Science Foundation of China [81170486, 30500603, 81170485, 30871104, 81101498]
  2. Jiangsu Province's Medical Elite Program [RC2011168]
  3. International Cooperation Program of Jiangsu Province [BZ2010041]
  4. Jiangsu Province Health Agency Foundation [K201107]
  5. Program for Development of Innovative Research Team in the First Affiliated Hospital of NJMU
  6. Priority Academic Program Development of Jiangsu Higher Education Institutions

Ask authors/readers for more resources

Impaired cell death program has been noted as one of the hallmarks of chronic lymphocytic leukemia (CLL) and contributes to its accumulation of malignant monoclonal B cells as well as to chemotherapy resistance. A cell can die through the apoptosis or necrosis pathway. Recent investigations suggest that in apoptotic-deficient conditions, such as most types of cancer, a process of programmed necrosis, called necroptosis, prevails. However, the detailed molecular mechanisms underlying this alternative cell death pathway are still not fully understood. Here we demonstrate that CLL cells failed to undergo necroptosis upon stimulation of TNF alpha combined with pan-caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD). Two core components of necroptotic machine, RIP3 and deubiquitinase cylindromatosis (CYLD), are markedly downregulated in CLL. Moreover, we identified lymphoid enhancer-binding factor 1 (LEF1), a downstream effector of the Wnt/beta-catenin pathway, as a transcription repressor of CYLD in CLL. Knocking down LEF1 sensitizes CLL cells to TNF alpha/zVAD-induced necroptosis. The present investigation provides the first evidence that CLL cells have defects not only in apoptotic program but also in necroptotic signaling. Targeting the key regulators of necroptotic machine, such as LEF1, to restore this pathway may represent a novel approach for CLL treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available